Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
$7.48
-1.1%
$9.37
$3.28
$14.69
$602.93M2.131.24 million shs1.58 million shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$1.20
-3.2%
$1.16
$0.33
$1.51
$124.45M1.241.04 million shs1.05 million shs
Organogenesis stock logo
ORGO
Organogenesis
$3.96
-2.0%
$4.65
$2.61
$6.71
$512.51M1.68810,225 shs546,525 shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$11.01
+1.8%
$9.40
$6.19
$13.16
$607.38M1.492.67 million shs2.89 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
-1.06%+7.94%-22.08%-33.81%+121.30%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-3.23%-13.04%-8.40%+1.69%-8.40%
Organogenesis stock logo
ORGO
Organogenesis
-1.98%-7.69%-18.52%-7.91%+31.13%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
+1.76%+12.92%+37.97%-12.13%+29.99%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
$7.48
-1.1%
$9.37
$3.28
$14.69
$602.93M2.131.24 million shs1.58 million shs
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
$1.20
-3.2%
$1.16
$0.33
$1.51
$124.45M1.241.04 million shs1.05 million shs
Organogenesis stock logo
ORGO
Organogenesis
$3.96
-2.0%
$4.65
$2.61
$6.71
$512.51M1.68810,225 shs546,525 shs
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$11.01
+1.8%
$9.40
$6.19
$13.16
$607.38M1.492.67 million shs2.89 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
-1.06%+7.94%-22.08%-33.81%+121.30%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-3.23%-13.04%-8.40%+1.69%-8.40%
Organogenesis stock logo
ORGO
Organogenesis
-1.98%-7.69%-18.52%-7.91%+31.13%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
+1.76%+12.92%+37.97%-12.13%+29.99%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
2.83
Moderate Buy$13.4279.41% Upside
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
2.50
Moderate Buy$5.00316.67% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.25
Hold$7.3385.19% Upside
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.63
Moderate Buy$24.00117.98% Upside

Current Analyst Ratings Breakdown

Latest ONCY, NAGE, ZVRA, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/8/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
10/8/2025
Organogenesis stock logo
ORGO
Organogenesis
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
9/27/2025
Organogenesis stock logo
ORGO
Organogenesis
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/27/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/26/2025
Organogenesis stock logo
ORGO
Organogenesis
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$7.00
8/18/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
8/13/2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/13/2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$7.00
(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
$99.60M5.99$0.06 per share127.81$0.60 per share12.47
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/A$0.05 per shareN/A
Organogenesis stock logo
ORGO
Organogenesis
$482.04M1.04$0.20 per share19.36$2.09 per share1.89
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$23.61M26.17N/AN/A$0.74 per share14.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
$8.55M$0.2135.62N/A15.24%23.12%15.53%N/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$23.14M-$0.27N/AN/AN/AN/A-438.11%-143.90%11/11/2025 (Estimated)
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.14N/AN/AN/A-1.92%-0.37%-0.20%11/6/2025 (Estimated)
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
-$105.51M-$0.21N/A55.05N/A4.33%-112.40%-37.67%11/11/2025 (Estimated)

Latest ONCY, NAGE, ZVRA, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.07N/AN/AN/A$134.10 millionN/A
8/12/2025Q2 2025
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
$1.43-$0.06-$1.49$1.21$22.49 million$25.88 million
8/8/2025Q2 2025
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
-$0.11-$0.05+$0.06-$0.05N/AN/A
8/7/2025Q2 2025
Organogenesis stock logo
ORGO
Organogenesis
-$0.01-$0.09-$0.08-$0.10$104.75 million$101.01 million
8/6/2025Q2 2025
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
$0.02$0.04+$0.02$0.04$28.55 million$31.12 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
N/AN/AN/AN/AN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
N/A
3.88
3.24
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
N/A
2.88
2.88
Organogenesis stock logo
ORGO
Organogenesis
N/A
3.95
3.45
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
0.52
7.85
7.81

Institutional Ownership

CompanyInstitutional Ownership
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
15.41%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
6.82%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
35.03%

Insider Ownership

CompanyInsider Ownership
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
9.39%
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
0.10%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Niagen Bioscience, Inc. stock logo
NAGE
Niagen Bioscience
12079.75 million72.26 millionN/A
Oncolytics Biotech Inc. stock logo
ONCY
Oncolytics Biotech
30100.36 million100.26 millionNot Optionable
Organogenesis stock logo
ORGO
Organogenesis
950126.86 million85.00 millionOptionable
Zevra Therapeutics, Inc. stock logo
ZVRA
Zevra Therapeutics
2056.13 million54.79 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Niagen Bioscience stock logo

Niagen Bioscience NASDAQ:NAGE

$7.48 -0.08 (-1.06%)
As of 10/10/2025 04:00 PM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Oncolytics Biotech stock logo

Oncolytics Biotech NASDAQ:ONCY

$1.20 -0.04 (-3.23%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$1.18 -0.02 (-2.00%)
As of 10/10/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$3.96 -0.08 (-1.98%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$3.92 -0.04 (-0.88%)
As of 10/10/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Zevra Therapeutics stock logo

Zevra Therapeutics NASDAQ:ZVRA

$11.01 +0.19 (+1.76%)
Closing price 10/10/2025 04:00 PM Eastern
Extended Trading
$10.57 -0.44 (-4.00%)
As of 10/10/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.